Matica Biotechnology Inc, a US-based contract development and manufacturing organisation, announced on Monday that it has signed a joint research agreement with Sartorius, a US-based international partner to the biopharmaceutical industry.
According to the contract, both firms will work on various studies together to streamline and optimise PAT technologies, automation software, and single-use platforms provided by Sartorius for large scale vector production.
Michael Stewart, chief technology officer at Matica Bio, said, 'The generation of in-line real-time process data is one of the most significant obstacles to achieving consistent, high-producing viral vector titers during development that can be translatable to large scale production. In many respects, what is going on inside a bioreactor or within downstream operations is still a black box to us. Matica Bio's development, manufacturing and quality teams have decades of viral vector production experience. Applying our expertise together with Sartorius' industry-leading single-use and PAT technologies will allow us to provide more robust, consistent results for our clients, guiding informed decision-making throughout the manufacturing process and accelerating the overall development timeline to the clinic and market.'
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval